Marc Hasenfuss Editor-at-large

The past 18 months have been tough for investors. Even the most wide-eyed small-cap punter would, by now, have developed a jaundiced outlook. The recent "bad let-downs" at respected blue-chip companies such as Aspen Pharmacare and Tongaat Hulett were just the kind of sentiment-souring episodes the JSE did not need. I reckon there’s more than a slim chance of more corporate shocks this year. Prolonged tough trading conditions might well have pressured incentivised executives into taking short-term decisions to prop up profits that might have disastrous longer-term implications. PODCAST: Understanding the vulnerability of the JSE. Subscribe: | Spotify | Apple Podcasts | Pocket Cast | In fact, it is strange to see so many large-cap counters, once market darlings, having a hard time convincing the market they are on the mend — stalwarts such as Mediclinic International, MTN, Brait, Tiger Brands, Woolworths, and Famous Brands.Perhaps the easiest thing to do this year is...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Times Select.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now